Eris Lifesciences Allots 24,396 Equity Shares Under ESOP-2021 Scheme, Paid-Up Capital Rises to ₹13,85,67,256
Eris Lifesciences allotted 24,396 equity shares on May 11, 2026 under its ESOP-2021 Scheme, covering grant years 2022, 2023, and 2024 at issue prices of Rs. 557.24, Rs. 510.32, and Rs. 728.16 per share respectively. The allotment increased the company's paid-up share capital from ₹13,85,42,887 to ₹13,85,67,256, with each equity share carrying a face value of ₹1. The development was disclosed to BSE Limited and the National Stock Exchange of India Limited by Company Secretary Milind Talegaonkar.

*this image is generated using AI for illustrative purposes only.
Eris Lifesciences announced the allotment of 24,396 equity shares on May 11, 2026, pursuant to the exercise of stock options under its ESOP-2021 Scheme. The allotment was formally communicated to both BSE Limited and the National Stock Exchange of India Limited by Milind Talegaonkar, Company Secretary and Compliance Officer.
ESOP-2021 Scheme Allotment Details
The allotment under the ESOP-2021 Scheme spans three grant years, with varying issue prices per share for each year. The following table provides a breakdown of the shares allotted and the corresponding issue prices:
| Parameter: | Grant Year 2022 | Grant Year 2023 | Grant Year 2024 |
|---|---|---|---|
| ESOP Scheme: | ESOP-2021 Scheme | ESOP-2021 Scheme | ESOP-2021 Scheme |
| Equity Shares Allotted: | 6,415 | 8,281 | 9,673 |
| Issue Price Per Share: | Rs. 557.24 | Rs. 510.32 | Rs. 728.16 |
The total of 24,396 equity shares allotted on May 11, 2026 reflects the cumulative exercise of options across these three grant years under the ESOP-2021 Scheme.
Impact on Paid-Up Share Capital
Following the allotment, the paid-up share capital of Eris Lifesciences has been revised upward. Each equity share carries a face value of ₹1. The table below summarises the change in paid-up share capital:
| Metric: | Details |
|---|---|
| Pre-Allotment Paid-Up Capital: | ₹13,85,42,887 (13,85,42,887 equity shares of ₹1 each) |
| Post-Allotment Paid-Up Capital: | ₹13,85,67,256 (13,85,67,256 equity shares of ₹1 each) |
| Shares Allotted: | 24,396 equity shares |
| Allotment Date: | May 11, 2026 |
The disclosure was made in compliance with applicable listing obligations, and the information has been submitted for record with both stock exchanges. The communication was signed by Milind Talegaonkar, Company Secretary and Compliance Officer, bearing ICSI Membership No. A26493, with a digital signature dated May 11, 2026.
Historical Stock Returns for Eris Lifesciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.99% | -1.08% | -2.37% | -10.61% | -6.07% | +102.45% |
How might the continued dilution from ESOP-2021 Scheme exercises impact Eris Lifesciences' earnings per share trajectory over the next few quarters?
Given the varying issue prices across grant years (Rs. 557–728), what does the pattern of employee option exercises suggest about insider confidence in Eris Lifesciences' future stock performance?
Are there additional tranches of unexercised options under the ESOP-2021 Scheme that could further dilute the paid-up share capital, and what is the potential total dilution exposure?


































